期刊文献+

糖尿病患者心血管疾病发病机制的研究进展 被引量:12

Research Progress on the Pathogenesis of Cardiovascular Disease in Patients with Diabetes
下载PDF
导出
摘要 多项流行病学研究证实,糖尿病是包括心肌梗死、卒中、外周血管疾病及心力衰竭在内的各种心血管疾病发生、发展的主要危险因素。糖尿病患者中动脉粥样硬化和心血管疾病患病率逐渐升高,可能是多种因素所致。在这个过程中可能的机制包括直接和间接影响高血糖和糖基化终末产物、血管内皮功能受损、增加亚临床炎症和血栓形成和纤溶异常。因此,为了减少糖尿病的卫生负担有必要积极地预防和治疗心血管疾病。 It has been demonstrated by multiple epidemiologic studies that diabetes is a major risk factor for the incidence and development of all kinds of cardiovascular diseases,including myocardial infarction,stroke,peripheral vascular disease,and heart failure.Incidence rates of atherosclerosis and cardiovascular diseases in patients with diabetes have been gradually increasing,and the causes are multifactorial.Potential mechanisms involved in this process include the direct and indirect effects of hyperglycemia and advanced glycation end products,impaired endothelial function,increased subclinical inflammation,and abnormalities of thrombosis and fibrinolysis.Therefore,it is necessary to positively prevent and treat cardiovascular diseases in order to release the burden of healthcare for diabetes patients.
作者 刘超 杜万红
出处 《医学综述》 2015年第1期103-105,共3页 Medical Recapitulate
关键词 糖基化终末产物 血管内皮功能受损 炎症 血栓 纤溶 Advanced glycation end products Impaired endothelial function Inflammation Thrombosis, Fibrinolysis
  • 相关文献

参考文献20

  • 1Arakawa M,Mita T,Azuma K,et al.Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist,exendin-4[J].Diabetes,2010,59(4):1030-1037.
  • 2Emerging Risk Factors Collaboration,Sarwar N,Gao P,et al.Diabetes mellitus,fasting blood glucose concentration,and risk of vascular disease:a collaborative meta-analysis of 102 prospective studies[J].Lancet,2010,375(9733):2215-2222.
  • 3Duckworth W,Abraira C,Moritz T,et al.Glucose control and vascular complications in veterans with type 2 diabetes[J].N Engl J Med,2009,360(2):129-139.
  • 4Patel A,Mac Mahon S,Chalmers J,et al.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes[J].N Engl J Med,2008,358(24):2560-2572.
  • 5Gerstein HC,Miller ME,Byington RP,et al.Effects of intensive glucose lowering in type 2 diabetes[J].N Engl J Med,2008,358(24):2545-2559.
  • 6Egan JM,Bulotta A,Hui H,et al.GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells[J].Diabetes Metab Res Rev,2003,19(4):115-123.
  • 7Rosenstock J,Baron MA,Dejager S,et al.Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes:a24-week,double-blind,randomized trial[J].Diabetes Care,2007,30(6):217-223.
  • 8De Fronzo RA,Ratner RE,Han J,et al.Effects of exenatide(exendin-4)on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes[J].Diabetes Care,2005,28(3):1092-1100.
  • 9Horton ES,Silberman C,Davis KL,et al.Weight loss,glycemic control,and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database[J].Diabetes Care,2010,33(1):1759-1765.
  • 10Nauck M,Frid A,Hermansen K,et al.Efficacy and safety comparison of liraglutide,glimepiride,and placebo,all in combination with metformin,in type 2 diabetes:the LEAD(liraglutide effect and action in diabetes)-2 study[J].Diabetes Care,2009,32(7):84-90.

同被引文献144

引证文献12

二级引证文献117

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部